Verastem Oncology to Participate in Upcoming September Investor Conferences
Verastem reported $30.9M in revenue and a $209.5M net loss for fiscal 2025.
See the full VSTM financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.
Verastem Oncology to Participate in Upcoming September Investor Conferences
Verastem Oncology (VSTM)/b) will participate in multiple September 2026 healthcare investor conferences, including Wells Fargo, Cantor, and H.C.
BOSTON--(BUSINESS WIRE)--
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate at the Wells Fargo 21st Annual Healthcare Conference on Sept.8 in Boston and present at the following investor conferences:
Cantor Global Healthcare Conference in New York City: September 10, 8:35-9:05am ET
H.C. Wainwright Annual Global Investment Conference in New York City: September 14, 12:00-12:30 pm ET
A live webcast of the fireside chats can be accessed under “Events & Presentations” on the Company’s website at www.verastem.com. A replay of the webcasts will be archived on the website for approximately 90 days following the presentation.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI® FAKZYNJA® CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.
For Investor and Media Inquiries:
Julissa Viana
Senior Vice President, Corporate Communications,
Investor Relations & Patient Advocacy
investors@verastem.com or
media@verastem.com
Source: Verastem Oncology
Key Terms
ras/mapk pathwaytechnical
A cellular signaling route that acts like a chain of command inside cells to tell them when to grow, divide, or die; when parts of this RAS/MAPK pathway are stuck “on,” it can drive uncontrolled cell growth that leads to cancer. Investors care because drugs, tests, or diagnostics that target or measure this pathway can become valuable products, affect drug approval chances, and change a company’s revenue or risk profile much like fixing a critical production line in a factory.
kras g12dmedical
KRAS G12D is a specific change in the KRAS gene where one building block in the cell’s instruction manual is swapped, causing the KRAS protein to get stuck in an “on” position and drive uncontrolled cell growth. Investors care because this switch is a common cause of certain cancers and creates a clear target for tests and treatments; successful drugs or diagnostics aimed at KRAS G12D can affect drug sales, trial outcomes, and regulatory approvals.
raf/mek inhibitionmedical
RAF/MEK inhibition is a drug mechanism that blocks two proteins, RAF and MEK, which act like relay stations in a cellular growth signaling pathway (the MAPK pathway). For investors, it matters because many targeted cancer therapies use these inhibitors to slow or stop tumor cell growth, and effectiveness, safety, or resistance to RAF/MEK inhibitors can affect a drug’s clinical success, regulatory outcomes, and commercial potential.
fak inhibitionmedical
Inhibiting focal adhesion kinase (FAK) means blocking a cellular enzyme that helps cells stick to their surroundings, move, and send survival signals. As a drug mechanism in oncology and fibrosis research, FAK inhibition can slow tumor growth, limit spread, or make other treatments more effective; investors track it because it defines a therapy’s biological rationale, clinical development strategy, and potential market value, like cutting the communication lines a disease uses to spread.
